Local, Controlled Release In Vivo of Vascular Endothelial Growth Factor Within a Subcutaneous Scaffolded Islet Implant Reduces Early Islet Necrosis and Improves Performance of the Graft

Islet transplantation remains the only alternative to daily insulin therapy for control of type 1 diabetes (T1D) in humans. To avoid the drawbacks of intrahepatic islet transplantation, we are developing a scaffolded islet implant to transplant islets into nonhepatic sites. The implant test bed, siz...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebe, John A., Preisinger, Anton, Gooden, Michel D., D’Amico, Leonard A., Vernon, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038045/
https://www.ncbi.nlm.nih.gov/pubmed/29756517
http://dx.doi.org/10.1177/0963689718754562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038045/
https://www.ncbi.nlm.nih.gov/pubmed/29756517
http://dx.doi.org/10.1177/0963689718754562

Ejemplares similares